Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells
- PMID: 18796623
- DOI: 10.1182/blood-2008-02-139725
Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells
Abstract
Notch signaling is involved in tumorigenesis, but its role in B-chronic lymphocytic leukemia (B-CLL) pathogenesis is not completely defined. This study examined the expression and activation of Notch receptors in B-CLL cells and the role of Notch signaling in sustaining the survival of these cells. Our results show that B-CLL cells but not normal B cells constitutively express Notch1 and Notch2 proteins as well as their ligands Jagged1 and Jagged2. Notch signaling is constitutively activated in B-CLL cells, and its activation is further increased in B-CLL cells, which resist spontaneous apoptosis after 24-hour ex vivo culture. Notch stimulation by a soluble Jagged1 ligand increases B-CLL cell survival and is accompanied by increased nuclear factor-kappa B (NF-kappaB) activity and cellular inhibitor of apoptosis protein 2 (c-IAP2) and X-linked inhibitor of apoptosis protein (XIAP) expression. In contrast, Notch-signaling inhibition by the gamma-secretase inhibitor I (GSI; z-Leu-Leu-Nle-CHO) and the specific Notch2 down-regulation by small-interfering RNA accelerate spontaneous B-CLL cell apoptosis. Apoptotic activity of GSI is accompanied by reduction of NF-kappaB activity and c-IAP2 and XIAP expression. Overall, our findings show that Notch signaling plays a critical role in B-CLL cell survival and apoptosis resistance and suggest that it could be a novel potential therapeutic target.
Comment in
-
B-CLL kicks it up a Notch.Blood. 2009 Jan 22;113(4):765-6. doi: 10.1182/blood-2008-10-182998. Blood. 2009. PMID: 19164502 No abstract available.
Similar articles
-
γ-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation.Int J Cancer. 2013 Apr 15;132(8):1940-53. doi: 10.1002/ijc.27863. Epub 2012 Oct 17. Int J Cancer. 2013. PMID: 23001755
-
IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation.Cell Death Dis. 2018 Nov 26;9(12):1160. doi: 10.1038/s41419-018-1185-6. Cell Death Dis. 2018. PMID: 30478302 Free PMC article.
-
Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors.EMBO J. 1999 May 17;18(10):2803-11. doi: 10.1093/emboj/18.10.2803. EMBO J. 1999. PMID: 10329626 Free PMC article.
-
Blockade of Jagged/Notch pathway abrogates transforming growth factor β2-induced epithelial-mesenchymal transition in human retinal pigment epithelium cells.Curr Mol Med. 2014 May;14(4):523-34. doi: 10.2174/1566524014666140331230411. Curr Mol Med. 2014. PMID: 24694299 Review.
-
[Notch signal pathway and chronic lymphocytic leukemia].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Oct;22(5):1472-5. doi: 10.7534/j.issn.1009-2137.2014.05.055. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014. PMID: 25338610 Review. Chinese.
Cited by
-
NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients.BMC Cancer. 2013 Jun 4;13:274. doi: 10.1186/1471-2407-13-274. BMC Cancer. 2013. PMID: 23734977 Free PMC article.
-
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.Blood. 2022 May 26;139(21):3148-3158. doi: 10.1182/blood.2021014162. Blood. 2022. PMID: 35303070 Free PMC article. Clinical Trial.
-
CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.Haematologica. 2019 Feb;104(2):226-235. doi: 10.3324/haematol.2018.197152. Epub 2019 Jan 10. Haematologica. 2019. PMID: 30630983 Free PMC article. Review.
-
Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1.Front Oncol. 2022 Jan 6;11:777587. doi: 10.3389/fonc.2021.777587. eCollection 2021. Front Oncol. 2022. PMID: 35070982 Free PMC article.
-
Precision Medicine Management of Chronic Lymphocytic Leukemia.Cancers (Basel). 2020 Mar 10;12(3):642. doi: 10.3390/cancers12030642. Cancers (Basel). 2020. PMID: 32164276 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous